Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, announced today that the results of the Phase 2 study of its lead compound, CX-8998, for essential tremor will be featured in a platform presentation during the American Academy of Neurology 71st Annual Meeting, May 4 to May 10, 2019 in Philadelphia, PA.

Cavion is developing oral small molecules designed to selectively modulate T-type calcium channel activity in the central nervous system, acting as a biological “pacemaker” to help restore the brain’s natural rhythms. The company’s lead candidate CX-8998 is a first-in-class T-type calcium channel modulator and is the most advanced late-stage small molecule currently in development for essential tremor. CX-8998 was evaluated in the T-CALM Study, a Phase 2, double-blind, placebo-controlled clinical trial of 95 patients with essential tremor conducted at 25 sites across the United States. Patients were randomized to one of two treatment arms, receiving either placebo or CX-8998. A majority of subjects (64%) took study drug on top of certain standard of care anti-tremor medications.

“I am pleased to present the results of our Phase 2 T-CALM proof-of-concept study of CX-8998 in essential tremor at the annual Academy meeting,” said Margaret Lee, Cavion Senior Vice President, Preclinical and Translational Sciences. “We look forward to discussing our clinical path forward as we work to address the unmet need in this devastating disorder that can rob people of their quality of life and has not seen any new approved drug therapies in more than three decades.”

The T-CALM study will be featured during Session S4: Clinical Trials in Movement Disorders in a platform session on Sunday, May 5:

“Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM)”

Session time: 2:17 pm
Session name: S4: Clinical Trials in Movement Disorders
Program Number: S4.008

About Cavion, Inc.

Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion’s portfolio of T-type calcium channel modulators is being developed to restore the brain’s natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson’s disease tremor, neuropathic pain, and epilepsy with absence seizures.

About Essential Tremor

About 10 million Americans and 42 million people worldwide are affected by essential tremor (ET), the most common movement disorder. ET is a progressive neurodegenerative disease that ranges from mild to fully debilitating, with significant effects on people’s quality of life and activities of daily living, such as eating and drinking, dressing, writing and typing. The condition can lead to social embarrassment, phobia, anxiety, and depression. With no new drugs approved for more than three decades, there is a need for new and effective options for patients with ET.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190424005265/en/